SCHEMBL3581385

SCHEMBL3581385

COc1nc(C(N)=O)cc2ccc[c]c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 2/20 0.37
POLB P06746 1/20 0.36
GRM2 Q14416 2/20 0.35
SQOR Q9Y6N5 1/20 0.34
LMNA P02545 1/20 0.34
ALDH1A1 P00352 3/20 0.34
KMT2A Q03164 1/20 0.34
PARP1 P09874 2/20 0.33
SIRT6 Q8N6T7 1/20 0.33
CDC7 O00311 1/20 0.33
CCNE1 P24864 1/20 0.33
CDK2 P24941 1/20 0.33
DBF4 Q9UBU7 1/20 0.33
HPGD P15428 2/20 0.33
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33
GAA P10253 1/20 0.33
NQO2 P16083 1/20 0.33
ACHE P22303 1/20 0.33
GLA P06280 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3585656 0.71 IRAK1 (0.43) NNMTPOLBALDH1A1PARP1HPGD
SCHEMBL3580784 0.67 APLNR (0.33) ALDH1A1KMT2A
SCHEMBL3586201 0.67 SLC9A1 (0.38) ALDH1A1KMT2AKDM4ESMN1; SMN2PIM1
SCHEMBL3574115 0.66 IKBKB (0.34) NNMTPOLBSQORALDH1A1PARP1
SCHEMBL2688401 0.65 NNMT (0.50) NNMTPOLBGRM2PARP1SIRT6
SCHEMBL5708926 0.65 NNMT (0.50) NNMTPOLBALDH1A1SIRT6CDC7
SCHEMBL19329369 0.64 PIM1 (0.49) NNMTLMNAALDH1A1KMT2APARP1
SCHEMBL18305261 0.64 NNMT (0.49) NNMTPOLBGRM2PARP1SIRT6
SCHEMBL5750475 0.64 KDM4E (0.49) POLBALDH1A1KMT2AHPGDKDM4E
SCHEMBL5223539 0.63 LMNA (0.48) NNMTPOLBGRM2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100081650-A1 Antimicrobial Compounds AXTEN JEFFREY MICHAEL 2010-04-01 US claimed
EP-1537123-B1 AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS GLAXO GROUP LTD (GB) 2009-04-29 EP claimed
EP-1463728-B1 FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION BRISTOL MYERS SQUIBB CO (US) 2009-01-14 EP claimed
US-20060189604-A1 Compounds GLAXO GROUP LIMITED (GB) 2006-08-24 US claimed
EP-2098526-B1 Nitrogen-containing bicyclic compounds active on chronic pain conditions NEUROTUNE AG (CH) 2014-01-15 EP disclosed
US-8334286-B2 Substituted pyrrolo[1,2-A] pyrazines, compositions containing these, processes of making these, and uses thereof NEUROTUNE AG (CH) 2012-12-18 US disclosed
US-20100081650-A1 Antimicrobial Compounds AXTEN JEFFREY MICHAEL 2010-04-01 US disclosed
US-7622481-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2009-11-24 US disclosed
EP-2098526-A1 Nitrogen-containing bicyclic compounds active on chronic pain conditions Neurotune AG (CH) 2009-09-09 EP disclosed
WO-2009103176-A1 NITROGEN-CONTAINING BYCYCLIC COMPOUNDS ACTIVE ON CHRONIC PAIN CONDITIONS NEUROTUNE AG (CH) 2009-08-27 WO disclosed
EP-1537123-B1 AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS GLAXO GROUP LTD (GB) 2009-04-29 EP disclosed
EP-1463728-B1 FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION BRISTOL MYERS SQUIBB CO (US) 2009-01-14 EP disclosed
US-20060189604-A1 Compounds GLAXO GROUP LIMITED (GB) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189604-A1 Compounds ELANE, PIGS, SDHA NNMT 2003/4885POLB 1252/4885GRM2 4799/4885
US-20100081650-A1 Antimicrobial Compounds ELANE, NISCH, PIGS NNMT 3174/4885POLB 1370/4885GRM2 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.